Voyageur Pharmaceuticals announces new line of Barium Contrast Formulations setting new standard

Proactive - Interviews for investors

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to announce the successful completion of formulation work for the company’s latest product line, which includes five Health Canada-licensed products. These advanced formulations are set to raise industry standards, offering enhanced value to healthcare providers and stakeholders. Willis also revealed the launch of two new product brands, Vision and Smooth barium contrast agents, aimed at improving versatility and performance in medical diagnostics. Classified as new drugs, these innovative products are poised to benefit from faster approval processes, significantly reducing costs and timelines compared to traditional New Drug Application (NDA) submissions. This move marks a shift away from generics, positioning Voyageur Pharmaceuticals as a more competitive force in the market. Voyageur has already completed several pilot test batches for its product suite and is now advancing to patient testing. The company is entering the final phase of clinical trials, where these products will be used in X-ray and Computed Tomography procedures, signaling significant progress toward full market deployment. Additionally, the company has appointed Dr. Iryna Saranchova as its new Chief Science Officer, pending regulatory approval. Dr. Saranchova is a recognized expert in clinical research and immunology, with a distinguished career that includes roles as Honorary Professor/Lecturer at the University of British Columbia’s Faculty of Medicine and Research Fellow at the Michael Smith Laboratories and Vancouver Prostate Center. Her expertise in biomarker discovery, clinical research, and immunotherapy development will be a key asset as Voyageur accelerates its scientific initiatives. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough, #Nanotechnology, #MedicalResearch, #Pharmaceuticals #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews